Investors Sour on Data Debut For Dimension’s Hemophilia Gene Therapy – Xconomy
Xconomy |
Investors Sour on Data Debut For Dimension's Hemophilia Gene Therapy
Xconomy Despite the early and in some cases stunning results produced by gene therapy treatments in handfuls of hemophilia patients, significant questions remain about their durability, safety, and how broadly they'll be used if they are ultimately shown to work. Dimension Therapeutics' gene therapy candidate for hemophilia B shows treatment benefit in early-stage study but … Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Regulation FD Disclosure Is Dimension Therapeutics Inc (DMTX)'s Fuel Running Low? The Stock Reaches Yearly Low Today |
